CD274 and triple-negative breast carcinoma: For example, in 2019, the FDA approved the combined treatment of atezolizumab [antiprogrammed death-ligand 1 (PD-L1)] with nab-PTX for PDL1-positive unresectable locally advanced or metastatic triple-negative breast cancer.